REPLIGEN CORP Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
REPLIGEN CORP (RGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 48.50% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2025-03-14
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 48.50%, a 4.12% increase from fiscal 2023.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 46.58%, a 5.96% increase from fiscal 2022.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 43.96%, a 2.89% decline from fiscal 2021.
- REPLIGEN CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2021 was 45.27%, a 11.01% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|---|
| 2024-12-31 | 48.50% 10-K · filed 2025-03-14 | |
| 2023-12-31 | 46.58% 10-K · filed 2025-03-14 | |
| 2022-12-31 | 43.96% 10-K · filed 2025-03-14 | |
| 2021-12-31 | 45.27% 10-K/A · filed 2024-11-18 | |
| 2020-12-31 | 50.87% 10-K · filed 2023-02-22 | |
| 2019-12-31 | 50.87% 10-K · filed 2022-02-17 | |
| 2018-12-31 | 50.87% 10-K · filed 2021-02-24 | |
| 2016-12-31 | 51.01% 10-K · filed 2019-03-01 | |
| 2015-12-31 | 51.89% 10-K · filed 2018-02-22 | |
| 2014-12-31 | 51.71% 10-K · filed 2017-02-23 | |
| 2013-12-31 | 53.63% 10-K · filed 2016-02-25 | |
| 2012-12-31 | 53.54% 10-K · filed 2015-03-17 | |
| 2011-12-31 | 55.76% 10-K · filed 2014-03-14 | 53.54% 10-K · filed 2013-03-15 |
| 2011-03-31 | 63.60% 10-K · filed 2013-03-15 | |
| 2010-12-31 | 63.60% 10-K · filed 2014-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |